Literature DB >> 14531942

Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects.

Fang Wen1, Jie Tan.   

Abstract

AIM: To investigate the risk factors and clinical significance of blood-lipid metabolic disorder in schizophrenic patients caused by phenothiazine treatment for long term (from 1 month to 25 years).
METHODS: Serum levels of apolipoprotein AI (apoAI), apolipoprotein B (apoB), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and total cholesterol (TC) were measured in 120 chronic schizophrenia patients, 50 vascular dementia, and 100 normal controls by the enzyme method and immune fluoroscopy turbidimetric method.
RESULTS: The patients with schizophrenia and vascular dementia had significantly lower content of apoAI, HDL-C, and apoAI/apoB than those in normal control (P<0.01). Their apoB and TG levels were higher than the healthy control group (P<0.01). The TG contents in the negative group and the vascular dementia group were obviously higher than the positive group (P<0.01) while there was no marked difference between the TC levels in the three groups and the normal control group (P>0.05).
CONCLUSION: The chronic schizophrenic patients have a blood-lipid metabolic disorder by long-term intake of phenothiazine drugs. It is suggested that the traditional treatment with antipsychotic should reformed, and that drugs of degrading lipid and coagulation should be used to prevent and reduce the risk factors causing the onset of cardiovascular and cerebrovascular diseases and delay the development of the disturbance of intelligence and dementia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531942

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  7 in total

1.  Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients.

Authors:  Y J La; C L Wan; H Zhu; Y F Yang; Y S Chen; Y X Pan; G Y Feng; L He
Journal:  J Neural Transm (Vienna)       Date:  2006-12-14       Impact factor: 3.575

2.  Genetic associations of brain structural networks in schizophrenia: a preliminary study.

Authors:  Kanchana Jagannathan; Vince D Calhoun; Joel Gelernter; Michael C Stevens; Jingyu Liu; Federico Bolognani; Andreas Windemuth; Gualberto Ruaño; Michal Assaf; Godfrey D Pearlson
Journal:  Biol Psychiatry       Date:  2010-08-05       Impact factor: 13.382

Review 3.  Synthesis and structural activity relationship study of antitubercular carboxamides.

Authors:  D I Ugwu; B E Ezema; F U Eze; D I Ugwuja
Journal:  Int J Med Chem       Date:  2014-12-30

4.  Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia.

Authors:  Anastasiia S Boiko; Irina A Mednova; Elena G Kornetova; Arkadiy V Semke; Nikolay A Bokhan; Anton J M Loonen; Svetlana A Ivanova
Journal:  Heliyon       Date:  2019-07-03

5.  Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia.

Authors:  Wenwang Rao; Xiangfei Meng; Keqing Li; Yunshu Zhang; Xiang Yang Zhang
Journal:  Ann Gen Psychiatry       Date:  2021-12-20       Impact factor: 3.455

6.  Lipid profile in antipsychotic drug users: A comparative study.

Authors:  Hamidreza Roohafza; Azam Khani; Hamid Afshar; Mohammad Garakyaraghi; Afshin Amirpour; Basir Ghodsi
Journal:  ARYA Atheroscler       Date:  2013-05

7.  Association between cognitive impairment and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia.

Authors:  Wenwang Rao; Yunshu Zhang; Keqing Li; Xiang Yang Zhang
Journal:  Aging (Albany NY)       Date:  2021-06-16       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.